C1 inhibitor (C1INH) is a serine proteinase inhibitor (serpin) that regulates activation of the classical complement pathway and the contact (kinin-generating) systems by inactivation of C1r, C1s, plasma kallikrein and factor XII. Heterozygosity for C1INH deficiency or for expression of a dysfunctional C1INH protein results in hereditary angioedema (HAE). In the first Aim, an animal model for HAE will be developed using gene targeting technology. We hypothesize that C1INH-/-mice will not survive and that C1NH +/- mice will develop angioedema. To test the hypothesis that angioedema is mediated via contact system activation, deficient mice will be reconstituted with recombinant C1INH mutants with altered target proteinase specificities, and will be mated with bradykinin receptor 2 (Bk2R) and with C2 deficient mice. To test the hypothesis that inhibition of bradykinin will interfere with symptoms, the HAE mice will the treated with Bk2R antagonists. The mechanism of action of androgens in angioedema also will be analyzed. To test the hypothesis that the contact system plays a role in the pathogenesis of septic shock, the susceptibility of C1INH +/- mice to endotoxin shock will be determined. Infusions of C1INH proteins with selective inhibitory activities will define the roles of the complement and contact systems.
The second Aim i s directed toward structure-function analyses. To test the hypothesis that stable complex formation requires extensive insertion of the reactive center loop (RCL) into beta sheet A, RCL mutants and mutants that alter the stability of sheet A will be examined. To test the hypothesis that sites within and outside the RCL determine target protease specificity, P2 mutants, distal loop mutants, and non-RCL mutants in alpha1-antitrypsin:C1INH chimeras will be tested. To test the hypothesis that amino terminal-truncated C1INH more efficiently inhibits surface associated proteases, its ability to inhibit immune complex-mediated complement activation, and inactivate high molecular weight kininogen (HK)-bound kallikrein and surface-bound factor XIIa will be examined. To compare and contrast the structure of C1INH with other serpins, recombinant truncated C1INH will be crystallized. In addition to definition of the biologic roles of C1INH and characterization of its function, these studies also may lead to improved therapy of HAE and of other diseases in which activation of the complement or contact systems plays a role.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
2R37HD022082-14
Application #
2752361
Study Section
Allergy and Immunology Study Section (ALY)
Program Officer
Moody, Sally Ann
Project Start
1987-04-01
Project End
2004-04-30
Budget Start
1999-06-04
Budget End
2000-04-30
Support Year
14
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Immune Disease Institute, Inc.
Department
Type
DUNS #
115524410
City
Boston
State
MA
Country
United States
Zip Code
02115
Mejia, Pedro; Diez-Silva, Monica; Kamena, Faustin et al. (2016) Human C1-Inhibitor Suppresses Malaria Parasite Invasion and Cytoadhesion via Binding to Parasite Glycosylphosphatidylinositol and Host Cell Receptors. J Infect Dis 213:80-9
Lu, Fengxin; Fernandes, Stacey M; Davis 3rd, Alvin E (2013) The effect of C1 inhibitor on myocardial ischemia and reperfusion injury. Cardiovasc Pathol 22:75-80
Davis 3rd, Alvin E; Lu, Fengxin; Mejia, Pedro (2010) C1 inhibitor, a multi-functional serine protease inhibitor. Thromb Haemost 104:886-93
Davis 3rd, Alvin E; Mejia, Pedro; Lu, Fengxin (2008) Biological activities of C1 inhibitor. Mol Immunol 45:4057-63
Davis 3rd, Alvin E (2008) Hereditary angioedema: a current state-of-the-art review, III: mechanisms of hereditary angioedema. Ann Allergy Asthma Immunol 100:S7-12
Davis 3rd, Alvin E; Cai, Shenghe; Liu, Dongxu (2007) C1 inhibitor: biologic activities that are independent of protease inhibition. Immunobiology 212:313-23
Liu, Dongxu; Lu, Fengxin; Qin, Gangjian et al. (2007) C1 inhibitor-mediated protection from sepsis. J Immunol 179:3966-72
Davis 3rd, Alvin E (2006) Mechanism of angioedema in first complement component inhibitor deficiency. Immunol Allergy Clin North Am 26:633-51
Cai, Shenghe; Dole, Vandana S; Bergmeier, Wolfgang et al. (2005) A direct role for C1 inhibitor in regulation of leukocyte adhesion. J Immunol 174:6462-6
Liu, Dongxu; Zhang, Dong; Scafidi, Jennifer et al. (2005) C1 inhibitor prevents Gram-negative bacterial lipopolysaccharide-induced vascular permeability. Blood 105:2350-5

Showing the most recent 10 out of 47 publications